Discontinuation report FORXIGA
| Report ID | 257638 |
| Drug Identification Number | 02435470 |
| Brand name | FORXIGA |
| Common or Proper name | Common or Proper name |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | DAPAGLIFLOZIN |
| Strength(s) | 10MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Packaging size |
| ATC code | A10BK |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for discontinuation | Raw material availability |
| Anticipated discontinuation date | 2021-01-01 |
| Actual discontinuation date | |
| Remaining supply date | |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-10-31 | French | Compare |
| v1 | 2025-10-31 | English | Compare |
Showing 1 to 2 of 2